Advanced Micro Devices
AMD
ASML Holding
ASML
Meta Platforms
META
Cisco
CSCO
Taiwan Semiconductor
TSM
US Stock MarketDetailed Quotes
YMAB Y-mAbs Therapeutics
- 8.000
- 0.0000.00%
Close Dec 27 16:00 ET
- 8.000
- 0.0000.00%
Post 16:29 ET
358.31MMarket Cap-14.81P/E (TTM)
8.030High7.660Low447.74KVolume7.910Open8.000Pre Close3.52MTurnover1.65%Turnover RatioLossP/E (Static)44.79MShares20.90052wk High3.88P/B216.60MFloat Cap6.48052wk Low--Dividend TTM27.07MShs Float55.215Historical High--Div YieldTTM4.63%Amplitude2.700Historical Low7.871Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Y-mAbs Therapeutics Stock Forum
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs Therapeutics (NASDAQ: YMAB)presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also...
No comment yet